Poolbeg Pharma PLC (LON:POLB – Get Free Report) shares fell 19% during trading on Friday . The stock traded as low as GBX 3.70 ($0.05) and last traded at GBX 3.89 ($0.05). 3,471,574 shares traded hands during trading, an increase of 0% from the average session volume of 3,471,285 shares. The stock had previously closed at GBX 4.80 ($0.06).
Wall Street Analyst Weigh In
Separately, Shore Capital restated a “house stock” rating on shares of Poolbeg Pharma in a research report on Thursday, January 2nd.
Get Our Latest Research Report on POLB
Poolbeg Pharma Stock Down 15.9 %
Poolbeg Pharma Company Profile
Poolbeg Pharma plc is focussed on the development and commercialisation of innovative medicines targeting serious diseases with a high unmet medical need. Its model focusses upon developing its exciting clinical assets and commercialising approved and marketed drugs to support the growth of the Company and the development of its robust pipeline of innovative products, thereby driving significant value creation.
Poolbeg is led by an experienced leadership team with a history of delivering significant shareholder value.
See Also
- Five stocks we like better than Poolbeg Pharma
- Russell 2000 Index, How Investors Use it For Profitable Trading
- Ray Dalio’s Bridgewater Loaded Up on These Stocks in Q4 2024
- Differences Between Momentum Investing and Long Term Investing
- Walmart Faces Tariff Headwinds, Consumer Trends Remain Positive
- Want to Profit on the Downtrend? Downtrends, Explained.
- Tesla: 2 Reasons to Buy, 1 Reason to Run
Receive News & Ratings for Poolbeg Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Poolbeg Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
